Direkt zum Inhalt
Merck
  • Aberrant liver insulin receptor isoform a expression normalises with remission of type 2 diabetes after gastric bypass surgery.

Aberrant liver insulin receptor isoform a expression normalises with remission of type 2 diabetes after gastric bypass surgery.

PloS one (2015-03-06)
Vinko Besic, Hongjun Shi, Richard S Stubbs, Mark T Hayes
ZUSAMMENFASSUNG

Type 2 diabetes mellitus (T2DM) results from a combination of progressive insulin resistance and loss of pancreatic beta cell function and/or mass. Insulin signalling occurs through the insulin receptor, (INSR) which is alternatively spliced into two isoforms: INSRA (-exon 11) and INSRB (+exon 11). Because the INSR isoforms have different functional characteristics, their relative expression ratio has been implicated in the pathogenesis of insulin resistance and T2DM. We studied levels of INSR isoform mRNA in liver samples taken from 46 individuals with or without T2DM at Roux-en-Y (RYGB) surgery, and on average 17 (± 5.6) months later in 16 of the same individuals (8 diabetic and non-diabetic patients). INSRA or INSRB was also overexpressed in HepG2 cells to ascertain their effect on AKT phosphorylation and PCK1 expression as markers of insulin-mediated metabolic signalling. We found the INSRB:A isoform ratio was reduced in individuals with T2DM in comparison to those with normal glucose tolerance and normalised with remission of diabetes. The INSRB:A ratio increased due to a reduction in the alternatively spliced INSRA isoform following remission of diabetes. Overexpressing INSRA isoform in HepG2 hepatoma cells reduced inhibition of PCK1 transcription and did not increase AKT phosphorylation in response to insulin load compared to the effect of overexpressing the B isoform. Data presented here revitalizes the role of the INSR isoforms in the pathogenesis of T2DM, and suggests that an abrogated INSRB:A ratio that favours the INSRA isoform may negatively impact insulin-mediated metabolic signalling.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Glycerin, ACS reagent, ≥99.5%
Sigma-Aldrich
Glycerin, Molecular Biology, ≥99.0%
Sigma-Aldrich
Glycerin, ReagentPlus®, ≥99.0% (GC)
Sigma-Aldrich
Natriumdodecylsulfat, BioReagent, suitable for electrophoresis, Molecular Biology, ≥98.5% (GC)
Sigma-Aldrich
Natriumdodecylsulfat, ≥99.0% (GC), dust-free pellets
Sigma-Aldrich
Natriumdodecylsulfat, ACS reagent, ≥99.0%
Sigma-Aldrich
Natriumdodecylsulfat -Lösung, BioUltra, Molecular Biology, 10% in H2O
Sigma-Aldrich
Natriumdodecylsulfat, ReagentPlus®, ≥98.5% (GC)
Sigma-Aldrich
Glycerin, ≥99.5%
Sigma-Aldrich
Glycerin -Lösung, 83.5-89.5% (T)
Sigma-Aldrich
Natriumdodecylsulfat, BioUltra, Molecular Biology, ≥99.0% (GC)
Sigma-Aldrich
Glycerin, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for electrophoresis, ≥99% (GC)
Sigma-Aldrich
Natriumdodecylsulfat -Lösung, BioUltra, 20% in H2O
Sigma-Aldrich
Glycerin, BioUltra, Molecular Biology, anhydrous, ≥99.5% (GC)
Supelco
Glycerin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Glycerin, BioXtra, ≥99% (GC)
Supelco
Natriumdodecylsulfat, dust-free pellets, suitable for electrophoresis, Molecular Biology, ≥99.0% (GC)
USP
Glycerin, United States Pharmacopeia (USP) Reference Standard
Supelco
Natriumdodecylsulfat, suitable for ion pair chromatography, LiChropur, ≥99.0%
Sigma-Aldrich
Bromphenolblau, Sulton Form, ACS reagent
Sigma-Aldrich
Glycerin, FCC, FG
Sigma-Aldrich
Bromphenolblau, titration: suitable
Sigma-Aldrich
Natriumdodecylsulfat, BioXtra, ≥99.0% (GC)
Sigma-Aldrich
Glycerin, meets USP testing specifications
Sigma-Aldrich
Anti-Aktin-Antikörper, Klon C4, ascites fluid, clone C4, Chemicon®
Sigma-Aldrich
Natriumdodecylsulfat, ≥98.0% (GC)
Sigma-Aldrich
Natriumdodecylsulfat, 92.5-100.5% based on total alkyl sulfate content basis
Supelco
Glycerin, analytical standard
Sigma-Aldrich
Natriumdodecylsulfat, ≥90% ((Assay))
Sigma-Aldrich
Natriumdodecylsulfat, tested according to NF, mixture of sodium alkyl sulfates consisting mainly of sodium dodecyl sulfate